Literature DB >> 18695742

Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits.

Emiko Kohno1, Saori Murase, Mayumi Nishikata, Noboru Okamura, Sumio Matzno, Takashi Kuwahara, Kenji Matsuyama.   

Abstract

PURPOSE: In order to identify methods for preventing phlebitis caused by intravenous administration of vinorelbine (VNR), we established a procedure for estimating the severity of phlebitis in an animal model.
METHODS: Four different factors (administration rate, dilution, flushing, and infusion of fat emulsion) were evaluated for alleviation of phlebitis caused by VNR infusion. VNR was diluted with normal saline to prepare test solutions with concentrations of 0.6 mg/mL or 0.3 mg/mL for infusion into the auricular veins of rabbits. Two days after VNR infusion, the veins were subjected to histopathological examination.
RESULTS: VNR did not cause obvious loss of venous endothelial cells, the most sensitive and common feature of phlebitis, but VNR infusion led to inflammatory cell infiltration, edema, and epidermal degeneration. Tissue damage was significantly decreased by shortening the administration time and by diluting the VNR solution for infusion from 0.6 mg/mL to 0.3 mg/mL. However, there was no effect of flushing with normal saline after VNR infusion, while treatment with fat emulsion before and after VNR infusion only had a minimal effect.
CONCLUSION: Rapid infusion and dilution are effective methods of reducing phlebitis caused by the infusion of VNR, but the efficacy of flushing with normal saline or infusion of fat emulsion was not confirmed.

Entities:  

Keywords:  infusion rate; phlebitis; rabbit ear vein; solution concentration; vinorelbine

Mesh:

Substances:

Year:  2008        PMID: 18695742      PMCID: PMC2500147          DOI: 10.7150/ijms.5.218

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


1. Introduction

Vinorelbine (VNR) is a semi-synthetic vinca alkaloid derived from vinblastine that is used to treat non-small cell lung cancer (NSCLC) and breast cancer. For the treatment of NSCLC, VNR is administered at a dose of 20 to 25 mg/m2 alone 1 or in combination with cisplatin 2 or gemcitabine 3, 4. VNR is also administered at a dose of 25 mg/m2 alone or combined with cisplatin or trastuzumab in patients with inoperable, advanced, and recurrent breast cancer, who have previously received anthracyclines and taxanes 5, 6. The main adverse effects of VNR are granulocytopenia, leucopenia, and thrombocytopenia, with granulocytopenia being the primary dose-limiting toxicity. Phlebitis is another problematic adverse effect of intravenous VNR, and the incidence of phlebitis (local venous toxicity) after a 6-min infusion of VNR has been reported as 16-33% 7-9. Phlebitis limits the continuation of chemotherapy by decreasing patient motivation and compliance. VNR has been reported to cause venous discoloration and chemical phlebitis proximal to the site of injection, as well as localized rashes and urticaria, blistering, and skin sloughing 10. It is a vesicant and venous irritant like other vinca alkaloids. Factors that influence the development of phlebitis include the quality of the vein selected, the size and type of catheter used, the duration of infusion, and the pH and osmolality of the drug solution. The Japanese package insert for VNR recommends dilution with 50 mL of normal saline or 5% glucose and administration over less than 10 min, followed by flushing of the vein but the effectiveness of this protocol has not been evaluated. The purpose of the present study was to establish an experimental method for estimating the severity of phlebitis caused by VNR in rabbits, and then to test various methods that have been reported for preventing phlebitis caused by intravenous VNR, including more rapid administration, dilution, flushing, and infusion of fat emulsion 11-13.

2. Materials and Methods

Animals

Male Japanese white rabbits (Std; JW, Japan SLC, Inc., Shizuoka, Japan) weighing between 2.3 and 3.5 kg were housed in individual cages in an animal room maintained at 23 ± 3ºC and 55 ± 10 % relative humidity with ventilation 13-16 times/hr and a 12-hr light-dark cycle. The rabbits were allowed free access to diet and water, except during treatment. This study was approved by the Committee on Animal Experiments of Mukogawa Women's University.

Drugs

Navelbine® Injection (VNR) was kindly provided by Kyowa Hakko Kogyo Co. (Tokyo, Japan). A 1- mL vial of Navelbine® Injection was diluted with normal saline (Otsuka Normal Saline; Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan) to provide either a 0.6 mg/mL or 0.3 mg/mL solution of VNR. In addition, normal saline and 20% fat emulsion (Intralipos® 20%: Otsuka Pharmaceutical Factory, Inc.) were tested to examine their influence on VNR-induced phlebitis.

Experimental procedure

Test solutions were infused through a plastic catheter (Surflo, 24 gauge, outer diameter of 0.67 mm and length of 19 mm; Terumo Co., Tokyo, Japan) into an ear vein using a peristaltic pump (Minipuls 2, Gilson, Inc., WI, USA) (Figure 1). Veins in both ears were employed to compare different infusion conditions. The dose of VNR was set at 1.5 mg/kg in all experiments. Rabbits were killed by an overdose of sodium pentobarbital (Nembutal®, Dainippon Sumitomo Pharmaceutical Co., Osaka, Japan) at 2 days after infusion. Two samples of the ear vein were obtained, including the region 3-10 mm from the catheter tip (proximal region) and the region 20-30 mm from the catheter tip (distal region) (Figure 1). These were fixed in phosphate-buffered saline containing 10% formalin. Then cross-sections of the ear vein were prepared and stained with hematoxylin and eosin (HE). Histopathological examination was performed blindly, with the findings being graded according to the criteria shown in Table 1. These criteria were based on those of Kuwahara 14, with the addition of epidermal degeneration.
Figure 1

Sites of histopathological examination. Two regions of the ear vein, one located 3-10 mm from the catheter tip (proximal region) and the other located 20-30 mm (distal region) from it, were sampled at 2 days after infusion.

Table 1

Criteria for histopathological examination

Influence of the infusion rate

In 8 rabbits, a 0.6 mg/mL solution of VNR was infused into one ear vein for 30 min at 5 mL/kg/hr as a control, and the same solution was infused into the contralateral ear vein for 10 min at 15 mL/kg/hr (3-fold faster). The concentration of VNR was selected to be similar to the clinical concentration range. Before and after VNR infusion, normal saline was infused into both veins for 24 min at 5 mL/kg/hr.

Influence of the concentration

In 8 rabbits, a 0.6 mg/mL solution of VNR was infused into one ear vein for 30 min at 5 mL/kg/hr as a control, and a 0.3 mg/mL solution of VNR was infused into the contralateral ear vein for 30 min at 10 mL/kg/hr.

Effect of flushing with normal saline

A 0.6 mg/mL solution of VNR was infused for 30 min at 5 mL/kg/hr into the right and left ear veins of 8 rabbits. In one ear vein, infusion of VNR was followed by flushing with 5 mL of normal saline for 1 min, while the other ear vein was not flushed as a control.

Effect of 20% fat emulsion

A 0.6 mg/mL solution of VNR was infused for 30 min at 5 mL/kg/hr into the right and left ear veins of 8 rabbits. In one ear vein, 20% fat emulsion (Intralipos®) was infused for 24 min at 5 mL/kg/hr both before and after VNR infusion. In the other ear vein, normal saline was infused in the same manner as a control.

Statistical analysis

The grade of each histopathological finding was compared between groups by the Wilcoxon rank sum test and p<0.05 was considered to indicate a significant difference.

3. Results

Figure 2 shows a representative photomicrograph of a normal vein without exposure to VNR and Table 2 summarizes the histopathological findings after infusion of VNR at a normal or rapid rate. Infusion of a 0.6 mg/mL solution of VNR for 30 min at 5 mL/kg/hr (control) only caused slight loss of venous endothelial cells (Grade 1) in the distal region of the vein in 1 of 8 animals. In addition, there was inflammatory cell infiltration (Grades 2-3) in the proximal and distal regions of the vein in 5 animals each, edema (Grades 1-2) of the proximal vein region in 3 animals and the distal region in 5 animals, and epidermal degeneration (Grades 1-3) at both the proximal and distal regions in all 8 animals (Figure 3). After infusion of the same solution 3 times more rapidly (10 min, 15 mL/kg/hr), there was inflammatory cell infiltration (Grades 1-2) at the proximal vein region in 4 out of 8 animals and at the distal region in 3 animals, but edema (Grade 2) was only found in the proximal region of 1 animal. Epidermal degeneration (Grades 1-3) still occurred at both the proximal and distal regions in 7 out of 8 animals. Edema of the distal region was significantly less severe in the rapid infusion group compared with the control infusion group (p<0.05).
Figure 2

Typical photomicrographs of an untreated ear vein.

Table 2

Influence of the infusion rate on histopathological changes at 2 days after VNR infusion. In 8 rabbits, a 0.6-mg/mL solution of VNR was infused into one ear vein for 30 min at 5 mL/kg/hr as a control, and the same solution was also infused into the contralateral ear vein for 10 min at 15 mL/kg/hr (3-fold faster).

RegionInfusion rateLoss of venous endothelial cellsp valueInflammatory cell infiltrationp valueEdemap valueEpidermal degenerationp value
Grade0123012301230123
ProximalControl8000N.S.3023N.S.5210N.S.0233N.S.
Rapid8000431070101241
DistalControl7100N.S.3032N.S.3320<0.050323N.S.
Rapid8000512080001340

Numbers in the table represent the number of observations. N.S.; not significant

Figure 3

Typical photomicrographs of an ear vein after VNR infusion. A 0.6-mg/mL solution of VNR was infused into an ear vein for 30 min at 5 mL/kg/hr, and the vein was subjected to pathological examination after 2 days.

The results of histopathological examination are shown in Table 3. Infusion of a 0.6 mg/mL solution of VNR (control solution) caused slight loss of venous endothelial cells (Grade 1) at the proximal vein region in 2 out of 8 animals and at the distal region in 3 animals, as well as inflammatory cell infiltration (Grades 1-2) in the proximal region of all 8 animals and the distal region of 7 animals. In addition, edema (Grades 1-3) was noted at the proximal region in 4 animals and at the distal region in 5 animals, while epidermal degeneration (Grades 2-3) was seen at both the proximal and distal regions in all 8 animals. The 0.3 mg/mL solution of VNR (diluted solution) caused slight loss of venous endothelial cells (Grade 1) at the proximal vein region in 3 out of 8 animals and at the distal region in 2 animals, inflammatory cell infiltration (Grades 1-3) in the proximal and distal regions of 6 animals, edema (Grade 2) at the proximal region in 1 animal and the distal region in 3 animals, and epidermal degeneration (Grades 1-3) at both the proximal and distal regions in all 8 animals. Significantly less severe epidermal degeneration at the proximal region was noted after infusion of the diluted solution (p<0.05).
Table 3

Influence of the concentration on histopathological changes at 2 days after VNR infusion. In 8 rabbits, a 0.6-mg/mL solution of VNR was infused into one ear vein for 30 min at 5 mL/kg/hr as a control, and a 0.3-mg/mL solution of VNR was infused into the contralateral ear vein for 30 min at 10 mL/kg/hr.

RegionSolution concentrationLoss of venous endothelial cellsp valueInflammatory cell infiltrationp valueEdemap valueEpidermal degenerationp value
Grade0123012301230123
ProximalControl6200N.S.0260N.S.4220N.S.0053<0.05
Dilution5300233070100260
DistalControl5300N.S.1160N.S.3131N.S.0053N.S.
Dilution6200232150300251

Numbers in the table represent the number of observations. N.S.; not significant

Table 4 shows a comparison of the histopathological grades between VNR infusion with and without a normal saline flush. Flushing with normal saline led to a slight reduction in the loss of venous endothelial cells, but the improvement was not statistically significant.
Table 4

Effect of flushing with normal saline on histopathological changes at 2 days after VNR infusion. A 0.6-mg/mL solution of VNR was infused for 30 min at 5 mL/kg/hr into the right and left ear veins of 8 rabbits. In one ear vein, VNR infusion was followed by flushing with normal saline (5 mL over 1 min), while the other ear vein was not flushed as a control.

RegionSaline flushLoss of venous endothelial cellsp valueInflammatory cell infiltrationp valueEdemap valueEpidermal degenerationp value
Grade0123012301230123
ProximalWithout flush4400N.S.1340N.S.1610N.S.0044N.S.
With flush7100105231310044
DistalWithout flush6200N.S.1160N.S.2240N.S.0062N.S.
With flush7100214131310143

Numbers in the table represent the number of observations. N.S.; not significant

The results of histopathological examinations are shown in Table 5. No significant differences were observed after infusion of fat emulsion.
Table 5

Effect of fat emulsion on histopathological changes at 2 days after VNR infusion. A 0.6-mg/mL solution of VNR was infused for 30 min at 5 mL/kg/hr into the right and left ear veins of 8 rabbits. In one ear vein, 20% fat emulsion (Intralipos®) was infused for 24 min at 5 mL/kg/hr before and after VNR infusion. In the other ear vein, normal saline was infused in the same manner as a control.

RegionFat emulsion treatmentLoss of venous endothelial cellsp valueInflammatory cell infiltrationp valueEdemap valueEpidermal degenerationp value
Grade0123012301230123
ProximalWithout treatment8000N.S.2042N.S.4310N.S.0071N.S.
With treatment8000143043100242
DistalWithout treatment8000N.S.1331N.S.4220N.S.0161N.S.
With treatment8000233034100350

Numbers in the table represent the number of observations. N.S.; not significant

4. Discussion

VNR is widely used to treat solid tumors such as NSCLC 1-4 and breast cancer 5, 6. Phlebitis due to infusion of VNR is the one of the complications that limits treatment. Various methods of avoiding such phlebitis have been reported 11-13, but none are completely effective. It was reported that rapid infusion and flushing are effective for reducing phlebitis in the clinical setting 7, so an infusion rate of less than 5 minutes 15 but more than 1 minute has been recommended for VNR 7. To clarify the most efficient methods of preventing VNR induced phlebitis, we evaluated the effects of the VNR infusion rate, VNR concentration, saline flushing, and infusion of fat emulsion on phlebitis in a rabbit auricular vein model. There is little histopathological information about the effects of VNR infusion in animals and humans. However, infusion into the auricular vein in rabbits has been often used to investigate phlebitis 16-18. In addition, we have already investigated the influence of osmolarity on phlebitis in this model 19, and the results were consistent with clinical data reported by Kerin and colleagues 20. Thus, it was thought that this model could be used to investigate phlebitis caused by the infusion of VNR. Infusion of VNR did not cause marked loss of venous endothelial cells, which is considered to be the most sensitive and common feature of phlebitis due to experimental infusion 16, but it caused epidermal degeneration in almost all cases (Table 3). These findings suggested that VNR has different characteristics from common chemical irritants that induce phlebitis. Although the reason for this difference is unclear, it seems likely that part of a dose of VNR infused into a peripheral vein escapes into the perivascular tissue and reaches the epidermis, where it causes the changes of “epidermal degeneration.” It has been reported that infusion of VNR over 6-10 minutes decreases the incidence of phlebitis compared with infusion over 20-30 minutes 9, and the frequency of phlebitis is even lower decreased with bolus administration over 1 min followed by flushing with normal saline 7. We also found that tissue damage was decreased by a shorter infusion time, suggesting that this rabbit model was appropriate to investigate VNR-related phlebitis. We confirmed that the infusion rate had an important influence on VNR-induced phlebitis. It has been suggested that dilution is effective for reducing phlebitis caused by various agents in humans and animals 21, 22. In this study, we confirmed that dilution could alleviate VNR-induced phlebitis, suggesting that the drug concentration could one of the important factors provoking its occurrence. Thus, it is probably better to dilute VNR before infusion. Flushing with normal saline after VNR infusion and infusion of fat emulsion both before and after VNR were also investigated in this study. Although flushing with normal saline led to a slight reduction in the loss of venous endothelial cells (Table 4), the effect was not significant. The manufacturer of VNR recommends flushing with >75-125 mL of fluid after infusion 23, but there is little information about the efficacy of flushing. We did not confirm its usefulness in this study, so further investigation is needed. Matsusune et al. reported that infusion of fat emulsion reduced phlebitis in patients receiving peripheral parenteral nutrition, and suggested that it had a protective effect on the peripheral veins 24. However, we did not observe any effect of fat emulsion on phlebitis caused by VNR, suggesting that its infusion might provide insufficient protection. Phlebitis is considered to be associated with the mechanism of action of VNR. Rapid infusion and dilution with normal saline were both effective for reducing phlebitis after VNR infusion. That is, the development of phlebitis was related to the amount of contact (infusion duration and solution concentration) between VNR and the vascular endothelium. Since greater blood flow allows a more rapid rate of administration and more dilution VNR, choosing a large vessel with rapid blood flow may also be effective for preventing phlebitis caused by VNR infusion. In conclusion, our results suggest that rapid administration and dilution of the infusion solution are effective methods for preventing VNR-induced phlebitis. Choosing a large vein might also have a preventive effect, but further studies are needed for confirmation.
  21 in total

1.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

Authors:  K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

2.  Effects of pH and osmolality on phlebitic potential of infusion solutions for peripheral parenteral nutrition.

Authors:  T Kuwahara; S Asanami; T Tamura; S Kaneda
Journal:  J Toxicol Sci       Date:  1998-02       Impact factor: 2.196

3.  Prevention of vinorelbine phlebitis with cimetidine. A two-step design study.

Authors:  M Vassilomanolakis; G Koumakis; V Barbounis; G Orphanos; A Efremidis
Journal:  Support Care Cancer       Date:  2001-03       Impact factor: 3.603

4.  Effect of pH in glucose infusions on development of thrombophlebitis.

Authors:  E W Fonkalsrud; J Murphy; F G Smith
Journal:  J Surg Res       Date:  1968-11       Impact factor: 2.192

5.  Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.

Authors:  Masakazu Toi; Toshiaki Saeki; Kenjiro Aogi; Muneaki Sano; Kiyohiko Hatake; Taro Asaga; Yutaka Tokuda; Shoshu Mitsuyama; Morihiko Kimura; Tadashi Kobayashi; Motoshi Tamura; Toshio Tabei; Eisei Shin; Reiki Nishimura; Shinji Ohno; Shigemitsu Takashima
Journal:  Jpn J Clin Oncol       Date:  2005-06-01       Impact factor: 3.019

6.  The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study.

Authors:  C Gridelli
Journal:  Oncologist       Date:  2001

7.  Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients.

Authors:  A Tononi; I Panzini; G Oliverio; E Pasquini; L Gianni; M Nicolini; A Ravaioli
Journal:  J Chemother       Date:  1997-08       Impact factor: 1.714

8.  Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.

Authors:  Kiyotaka Yoh; Seiji Niho; Koichi Goto; Hironobu Ohmatsu; Kaoru Kubota; Ryutaro Kakinuma; Nagahiro Saijo; Yutaka Nishiwaki
Journal:  Lung Cancer       Date:  2006-11-28       Impact factor: 5.705

Review 9.  Vinorelbine and venous irritation: optimal parenteral administration.

Authors:  Mário L de Lemos
Journal:  J Oncol Pharm Pract       Date:  2005-06       Impact factor: 1.809

10.  [Consideration of preventive free-flowing IV infusion method for vinorelbine].

Authors:  Yukio Suga; Yusuke Hara; Hideko Hashimoto; Jun Nishigami; Michie Shimizu; Hiroko Akasaka; Kyoko Hayashi; Miharu Yonejima; Makiko Nakamura; Masafumi Inokuchi; Kazuo Kasahara; Gen-ichi Nishimura; Ken-ichi Miyamoto
Journal:  Gan To Kagaku Ryoho       Date:  2007-08
View more
  3 in total

1.  Effect of external use of sesame oil in the prevention of chemotherapy-induced phlebitis.

Authors:  Nilufar Nekuzad; Tahereh Ashke Torab; Faraz Mojab; Hamid Alavi-Majd; Payam Azadeh; Gholamreza Ehtejab
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

2.  Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits.

Authors:  Emiko Kohno; Saori Murase; Kenji Matsuyama; Noboru Okamura
Journal:  Int J Med Sci       Date:  2009-08-06       Impact factor: 3.738

3.  Toxicity Assessment of PEG-PCCL Nanoparticles and Preliminary Investigation on Its Anti-tumor Effect of Paclitaxel-Loading.

Authors:  Wei Li; Wanyi Li; Yu Kuang; Ting Yang; Jie Zhu; Zilin Xu; Xiang Yuan; Mingyuan Li; Zhongwei Zhang; Yuan Yang
Journal:  Nanoscale Res Lett       Date:  2018-08-24       Impact factor: 4.703

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.